LG’s Gimiglo to challenge multinational firms

The domestic 460-billion won oral diabetes markets may be encountered with a fierce competition between domestic and foreign multinational drug corporations when LG Life Sciences’ diabetes treatment, Gemiglo, jumps in.

The Korea Food and Drug Administration said Wednesday that it has approved the manufacture and distribution of Gimiglo.

Gemiglo (gemigliptin) is the 19th new drug developed...